Clinical trial NCT02435927: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Official title: Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Solid Tumors
Lead sponsor: National Cancer Centre, Singapore
Sponsor class: OTHER
Collaborators: name: ASLAN Pharmaceuticals
name: National Medical Research Council (NMRC), Singapore
First posted: 2015-05-06
Enrollment: 60
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.

Detailed description: The study will use standard 3+3 design to determine the MTD (maximum tolerated dose) of ASLAN001 in combination with fixed dose of Oxaliplatin/Capecitabine (CAPOX) or 5-FU/leucovorin (mFolfox6).

MTD of ASLAN001 in combination with CAPOX will first be determined followed by the combination with mFolfox6.

The recommended Phase II dose will be the highest dose of the combination therapy that is considered to be tolerated in 6 patients.

Eligibility criteria: Inclusion Criteria:

1. Patients with metastatic solid tumours eligible for treatment with oxaliplatin in combination with capecitabine / 5-FU (fluorouracil) and leucovorin or who progressed following standard therapy or patients with EGFR (epidermal growth factor receptor ) or HER2 dysregulated tumours.
2. Patients with a partial gastrectomy may be allowed to participate in the study as long as they can take oral medications and meet all other inclusion/exclusion criteria.
3. Eastern Cooperative Oncology Group performance status of 0 or 1.
4. Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to enrolment:

   • Hematological function, as follows: Absolute neutrophil count ≥ 1.5 x 109/L. Platelet count ≥ 100 x 109/L. Hemoglobin ≥ 9 g/dL.

   • Coagulation function, as follows: Prothrombin time and activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.

   • Renal function, as follows: Creatinine clearance ≥ 50 mL/min as calculated by Cockcroft-Gault formula.

   • Hepatic function, as follows: Total bilirubin ≤ 1.5 x ULN. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present).
5. Patients undergoing mandatory biopsy in dose expansion of a non-DLT cohort should have any of the following:

   * known HER2 or EGFR dysregulation
   * Patients with T790M mutation will be excluded.
   * Co-expression of HER2 and EGFR
6. Archival tumour sample is available for molecular profiling, unless undergoing tumour biopsy as part of the trial.

Exclusion Criteria:

1. Patients with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy.
2. Patients receiving proton pump inhibitors or H2 antagonists for established, symptomatic gastro duodenal ulceration or gastroesophageal reflux disease. H2 antagonist can be prescribed after DLT (dose-limiting toxicity) period (the first 2 cycles) at the discretion of the investigator.
3. Patients with unresolved toxicities of grade 2 or more from prior anti-cancer therapies excluding alopecia.
4. Untreated or symptomatic central nervous system metastases. Patients with treated brain metastases stable for 3 months are eligible to enroll.
5. Major surgical procedures within 28 days prior to enrolment.
6. Clinically significant cardiovascular diseases that are symptomatic or uncontrolled.
7. Known active infection for human immunodeficiency virus, hepatitis B and C.
8. Pregnant or breast-feeding females.
9. Treatment with any of the following anti-cancer therapies prior to the first dose of study drugs within the stated timeframes

   * Cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment. Exception for weekly chemotherapy regimens, where a minimum of 2 week washout from the last dose is required.
   * Biological therapy (e.g., antibodies) within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks, whichever is shorter, prior to starting study drug
   * Continuous or intermittent small molecule therapeutics within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug
   * Any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shortest) prior to starting study drug
   * Wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug
   * Previous combination therapy with xeloda and oxaliplatin within 6 months of study treatment.
   * Previous combination therapy with Oxaliplatin, 5-FU and Leucovorin (mFolfox6) within 6 months of study treatment

Primary outcomes:
measure: Maximum tolerated dose (MTD) of ASLAN001 when used in combination with Oxaliplatin and Capecitabine (CAPOX) or Oxaliplatin and 5-FU with leucovorin (mFolfox6)
timeFrame: one year
Secondary outcomes:
measure: Pharmacokinetic parameter Area under the plasma concentration time curve (AUC)
timeFrame: Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 3
measure: Pharmacokinetic parameter Maximum plasma concentration (Cmax)
timeFrame: Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 3
measure: Pharmacokinetic parameter Minimum (trough) plasma concentration (Cmin)
timeFrame: Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 3
measure: Efficacy of ASLAN001 when given in combination in CAPOX or mFolfox6 as measured by the objective response rate (ORR)
timeFrame: one year
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National Cancer Centre
Study officials:
affiliation: National Cancer Centre, Singapore
name: Matthew CH Ng
role: PRINCIPAL_INVESTIGATOR
References: